EUVIMEDOpdag EUVIMED
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial

Britta S Bürker iD, Kristine V Brautaset Englund iD, Charlotte Myrdal Østby, Stein Andersson, Lars Gullestad iD, Kaspar Broch

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70370 ↗

At a glance

Klinische Studie (Phase II) in Clinical Transplantation, 2025. Written by Britta S Bürker and 5 co-authors. Institution: Norwegian National Unit for Sensory Loss and Mental Health, Oslo University Hospital, Oslo, Norway. Major MEDLINE topics: Anemia, Iron-Deficiency, Cognition, Cognitive Dysfunction, Dietary Supplements. 24 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Cognitive dysfunction after successful heart transplantation (HTx) is not uncommon. Lower hemoglobin levels have previously been associated with cognitive dysfunction in heart transplant recipients (HTx recipients). In a randomized, placebo‐controlled, double‐blind treatment trial, we assessed as a pre‐specified secondary outcome whether a single intravenous iron supplement for iron deficiency in HTx recipients resulted in changes in cognitive function after 6 months.

Methods

In the “Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients” (IronIC) trial, we assessed cognitive function at baseline and at 6‐month follow‐up with the following tests of the Cambridge Neuropsychological Test Automated Battery: Reaction Time, Paired Associates Learning, and Spatial Working Memory. Of 94 participants with cognitive data at baseline and follow‐up, 49 were randomized to the single intravenous iron supplement, while 45 received placebo.

Results

Raw score changes from baseline to follow‐up did not differ statistically significantly between study groups (two measures of each test analyzed). In the total sample, 27%–44% of participants performed at baseline at least one standard deviation below the normative mean on measures of memory and working memory/executive functions. Exploratory analyses indicated that performance on measures of memory might decrease more than expected with increasing age.

Conclusion

A single intravenous iron supplement for iron deficiency in HTx recipients did not result in statistically significant cognitive changes after 6 months. The group as a whole performed approximately half a standard deviation below the normative mean on measures of memory and working memory/executive functions. Regular cognitive screening after HTx is recommended. Clinical Trial Registration Trial Registration: ClinicalTrials.gov identifier: NCT03662789

Subjects

MeSH terms (MEDLINE)

Anemia, Iron-DeficiencyCognitionCognitive DysfunctionDietary SupplementsHeart TransplantationIronAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodFollow-Up StudiesNeuropsychological TestsPrognosisRisk Factors

Author keywords

cognition disorderheart transplantationiron deficienciesmental processesrandomized controlled trial [publication type]

Substances

Iron

Authors and institutions

  • Norwegian National Unit for Sensory Loss and Mental Health, Oslo University Hospital, Oslo, Norway.
  • Department of Cardiology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
  • Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Department of Psychology, University of Oslo, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

ORCID profiles: Britta S Bürker, Kristine V Brautaset Englund, Lars Gullestad

Cite

APA

Bürker, B. S., Brautaset Englund, K. V., Myrdal Østby, C., Andersson, S., Gullestad, L., & Broch, K. (2025). Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial. Clinical Transplantation. https://doi.org/10.1111/ctr.70370

Vancouver

Bürker BS, Brautaset Englund KV, Myrdal Østby C, Andersson S, Gullestad L, Broch K. Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial. Clinical Transplantation. 2025. doi:10.1111/ctr.70370

BibTeX
@article{Brker2025,
  author = {Bürker, Britta S and Brautaset Englund, Kristine V and Myrdal Østby, Charlotte and Andersson, Stein and Gullestad, Lars and Broch, Kaspar},
  title = {Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70370}
}
Start for free →